According to scope of this report, digital pathology includes the acquisition, ma nagement, s hari ng, a nd interpretation of pathology information, which includes slides and data in a digital environment. The digital slides are created when glass slides are captured with a scanning device, in order to offer a high- resolution image, to be viewed on a computer screen or mobile device. The market size can be evaluated by collating the revenue generated from the products that are included in the scope of this report.

Owing to the rising prevalence of STDs and increasing need for proper diagnosis of the diseases, the market studied is growing rapidly. There is a negative social perception about STDs, as they are caused due to sexual interactions. Hence, people are more conscious about their privacy and social status, when it comes to STD testing, which is limiting the growth of the market studied.

Microfluidics is a medical approach involving the precise control of small fluid samples for medical analysis. The sample sizes in microfluidics range from microliters to picoliters. At such low volumes, the transportation of fluid is governed significantly by its mass. The market estimates provided in this report have been derived as a product of average selling price (ASP) and the volume sold in a year.

Pet humanization is a result of changes in people’s lifestyles, changing demographic patterns, and consumer preferences. Furthermore, the rising income, growing pet humanization, and people’s affection for pet strengthen the market studied. The shift in pet ‘ownership’ to ‘parenting’ has been a very crucial trend in the market studied, particularly in the developed countries. Over one-third of the households in the developed countries own a pet. However, consumers are now becoming aware that pet food and home-made food consist of separate nutritional elements and that pets need to be fed a diverse range of food, as part of providing an adequate diet. Hence, the demand for high-quality pet food is increasing, supported by the rise in pet ownership.

Non-alcoholic steatohepatitis (NASH), a destructive form of non-alcoholic fatty liver disease (NAFLD), often progress to more severe disorders, such as cirrhosis and hepatocellular carcinoma. Therefore, it has been projected that NASH may even surpass the hepatitis C virus infection, becoming the major cause of liver transplantation, across the world, in the coming decade.

The report provides market dynamics and trends related to the global urinary self-catheter market. In addition, it presents the market estimations and forecast of the market. The study estimates the revenue generated from the sales of urinary self-catheter and not included urinary self-catheter service revenue. The valuations comprise revenue generated from urinary self-catheter, which are available as intermittent catheter and external catheter. Male type catheter and female type catheter are considered during market estimation. Furthermore, the report also excludes revenue generated from post-sale services of urinary self-catheter.

One of the major factors driving the market studied is the high prevalence of urologic conditions all over the world. The fact that kidney and urinary tract diseases account for about 830,000 deaths and 18,467,000 disability-adjusted life years annually, making it the12th leading cause of deaths, have majorly led to an increased demand in the equipment used in urological treatments.

It is estimated that more than 200 Mn people across the world suffer from peripheral artery diseases (PAD), and one in every 20 Americans, over the age of 50, suffers from PADs. An increase in the incidence of PADs has led vendors to focus more on developing stenting technologies in order to treat them. There has also been a steady rise in critical limb ischemia and limb salvage procedures in order to prevent amputations. These factors result in the growth of the interventional cardiology devices market

As per the scope of this report, healthcare BPO (business process outsourcing) refers to a process, in which the healthcare providers select the most suited third-party vendor for specific business processes. It allows the hospitals, diagnostic centers, pharmacists and medical professionals to spend their energy and valuable time on patient care. The market size provided in the report has been derived from the revenue generated by products. For estimating the market size we use the revenues from the product and services involved in the healthcare BPO market.

As a result of the growing demand for generic medicines and biologics, the capital-intensive nature of the business, and the complex manufacturing requirements, many pharmaceutical companies have identified the potential profitability in contracting with a CMO (contract manufacturing outsourcing) for both clinical and commercial stage manufacturing. Additionally, pharmaceutical companies have been directing their priorities toward the core areas of competency, and hence, prefer not to dispense available resources, expertise, and technology on formulating the final dose of medicines.

近日，中共中央、国务院发布《关于促进中医药传承创新发展的意见》。《意见》指出：中医药学是中华民族的伟大创造，是中国古代科学的瑰宝、也是打开中华文明宝库的钥匙；肯定了自党的十八大以来，中医药改革发展取得显著成绩；同时指出了中医药发展过程中的不足和薄弱，中医药传承不足、创新不够、作用发挥不充分，迫切需要深入实施中医药法，采取有效措施解决以上问题。《意见》从六个方面指明了促进中医药传承创新发展的方向，分别是：健全中医药服务体系；发挥中医药在维护和促进人民健康中的独特作用；大力推动中药质量提升和产业高质量发展；加强中医药人才队伍建设；促进中医药传承与开放创新发展和改革完善中医药管理体制机制。 

前言：我国医美行业在经历了2013-2017的快速增长后，由2018下半年进入行业洗牌阶段。面对日新月异的消费者需求，多数机构在迷茫中倒闭；投资者也逐渐对医美行业产生了疑问。本篇报告将从以下几个维度分析行业与机构，以在混沌中寻求生存。行业现状及未来空间，机构价值链现状，机构经营模式及行业趋势？

2015年开展全国消化内镜医师执业情况普查，以全面了解我国消化内镜医师人员现状和执业情况，为推动内镜专科医师的规范化培训、资格认证和准入工作做好准备。目前国内澳华光电等企业研发的电子内镜系统已达到国际先进水平，成本仅为进口内镜的一半。

本周药监局发布注射剂一致性评价征求意见稿，公立医院化药注射剂销售额达到5600亿，占化药院内市场份额的60%以上，远高于口服剂型。注射剂后续预计也将经历对产品质量提出要求、在过评企业较多后开始降价的情形。建议关注目前注射剂仿制品种海外获批较多的企业如普利制药。此外，卫健委发布《儿童青少年近视防控适宜技术指南》，角膜塑形镜作为科学矫正方法之一，市场空间广阔，建议关注欧普康视。

T中ab国le宠_S物um线m下ar渠y] 道占比与美国形成显著差异。中国以小型门店为主，宠物门店及杂货类零售商的份额逐年下滑，但是宠物医院渠道占比有上升的趋势，从2015 年占比6%，增长至2019 年8.6%。

本周申万医药指数下跌 1.04%，涨跌幅位列全行业第 28，跑输沪深 300 指数及创业板指数。本期周报我们对 2019Q3 基金医药持仓整体水平和重仓股情况进行了全方位分析，医药板块在 Q3 增仓较多，性价比凸显。

血制品来源于血浆，行业具有很强的政策和技术壁垒。国家对血制品实行严格监管，先后制定了批签发制度、对原材料血浆实行检疫期制度等，2001年起不再批准新的血制品企业，对血浆来源浆站设立也有严格的企业资格限定。行业发展先后经过了取消药价限制、“两票制”等重要节点，年初上海兴新事件之后预计行业会持续规范化，品种和浆源少而管理不足的企业可能会被淘汰，资源向产品丰富、浆站多、重研发的头部企业集中，行业将在严监管下保持有序发展。

目前君实、信达、恒瑞的 PD-1产品已经获批上市，百济神州处在 NDA 阶段，领先其他国内企业较多。按照目前的销售价格和赠药政策，国产 PD-1 单抗的年治疗费用在 10-15 万，较进口同类产品有较大优势。后续适应症拓展方面，各个企业广泛布局发病率较高的癌症种类，其中恒瑞的卡瑞利珠单抗有肝细胞癌、食管癌、非小细胞肺癌等适应症处在 NDA 阶段，进度领先。 

医保局发布DRGs标准，接下来国家DRGs试点工作将快速推进，而对于药企而言，产品能否进入DRG付费组成为关键，未来控费趋势将更为严格，药品和器械企业机遇和挑战并存。国务院正式发布《关于促进中医药传承创新发展的意见》，中药的重要作用进一步明确的同时，中医药行业标准提升，行业中短期或将面临转型升级阵痛期，长期看有利于优质中药企业发展。 

医药周观点：本周申万医药指数上涨0.74%，涨跌幅位列全行业第2，跑赢沪深300 指数及创业板指数。本期周报我们从基本面、估值、时机时点等层面为大家重新梳理了我们长期持续跟踪的重点标的【云南白药】的价9Z·1值和投资逻辑。对于整体板块，考虑目前医保资金压力不可逆转，顶层设计已定，一切环环相扣，医药正在进行结构优化（包括医保局带来的支付端变革优化和药监局主导的供给侧改革优化），我们正经历一个结构大优化、细分精彩纷呈的医药新时代。